Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sucampo Pharmaceuticals Inc (NASDAQ:SCMP)

10.20
Delayed Data
As of 3:59pm ET
 -0.15 / -1.45%
Today’s Change
9.30
Today|||52-Week Range
17.55
-24.72%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$481.8M

Company Description

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development, identification, acquisition, and delivery of innovative pharmaceutical products. It operates through the following geographic segments: Asia, the Americas, and Europe. It offers Lubiprostone, which treats chronic constipation, chronic idiopathic constipation in adults, irritable bowel syndrome with constipation in adult women, and opiod-induced constipation in adults with chronic non-cancer pain. The company was founded by Dr. Ryuji Ueno and Dr. Sachiko Kuno on December 5, 1996 and is headquartered in Rockville, MD.

Contact Information

Sucampo Pharmaceuticals, Inc.
805 King Farm Boulevard
Rockville Maryland 20850
P:(301) 961-3400
Investor Relations:
(240) 223-3718

Employees

Shareholders

Individual stakeholders69.92%
Other institutional29.15%
Mutual fund holders24.01%

Top Executives

Peter S. GreenleafChairman & Chief Executive Officer
Peter P. PfreundschuhChief Financial Officer
Peter LichtlenChief Medical Officer
Peter Alec KienerChief Scientific Officer
Matthias A. AlderExecutive Vice President